文献速递临床试验与 GCP

急性胆管炎充分内镜胆道引流后1天与4-7天抗生素治疗的随机对照试验(COBRA)研究方案

Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2026-02-14

COBRA是一项多中心、开放标签、平行组、结局评估盲法的随机对照非劣效性试验,计划纳入416例急性胆管炎患者,在充分内镜胆道引流后按1:1随机分为1天抗生素组与4-7天抗生素组。主要终点为临床治愈,即第14天无症状且第30天无复发或死亡。该试验旨在评估短期抗生素治疗是否不劣于较长疗程。

要点

  • 东京指南2018推荐充分胆道引流后抗生素治疗4-7天,但观察性数据提示更短疗程可能足够。
  • COBRA试验计划纳入416例急性胆管炎患者,1:1随机至1天或4-7天抗生素组。
  • 主要终点为临床治愈:第14天无症状且第30天无复发或死亡。

核心结论

  • 该试验评估急性胆管炎充分胆道引流后1天抗生素治疗与4-7天抗生素治疗相比是否安全有效。
  • 若得以证实,结果可能大幅减少抗生素暴露和医疗资源利用,有助于全球减少不必要抗生素治疗的努力。

研究设计与样本

  • COBRA试验为多中心、开放标签、平行组随机对照非劣效性试验,采用盲法结局评估。
  • 计划纳入416例急性胆管炎患者,按1:1比例随机分配至干预组(充分胆道引流后1天抗生素治疗)或对照组(充分胆道引流后4-7天抗生素治疗)。
  • 纳入因胆总管结石、良恶性远端胆道梗阻或远端胆道支架功能障碍所致急性胆管炎的患者。
  • 在ERCP实现充分胆道引流后进行随机化,并按随机化时血培养结果和胆管炎病因进行分层。
  • 主要排除标准包括随机化时合并胰腺炎、肝脓肿、胆囊炎及其他感染诊断,使用全身维持性抗生素,以及特定免疫抑制剂。

主要发现

  • 主要终点为临床治愈,定义为患者第14天无症状且第30天无复发或死亡。
  • 次要终点包括30天和90天全因死亡率、90天内胆管炎复发、从ERCP至首次复发的时间、90天内需抗生素治疗的其他后续感染、初始住院时长、30天内抗生素治疗天数、多重耐药(MDR)细菌后续感染、生活质量及成本效果。

关键数值与推荐

  • 东京指南2018推荐充分胆道引流后抗生素治疗4至7天。
  • 观察性数据提示更短疗程可能足够。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute cholangitis is an infection of the biliary tract that is managed with adequate biliary drainage combined with antibiotic treatment. The international Tokyo Guidelines 2018 recommend 4 to 7 days of antibiotic treatment after adequate biliary drainage, but observational data suggest shorter treatment may be sufficient. We assessed whether 1 day of antibiotic treatment is non-inferior to 4-7 days of antibiotic treatment for acute cholangitis after adequate biliary drainage. METHODS: The COBRA-trial is a multicentre, open-label, parallel group randomized controlled non-inferiority trial with blinded outcome assessment. A total of 416 patients with acute cholangitis will be randomly assigned in a 1:1 ratio to the intervention group (1 day of antibiotic treatment after adequate biliary drainage) or to the control group (4-7 days of antibiotic treatment after adequate biliary drainage). Patients with acute cholangitis due to common bile duct stones, benign or malignant distal biliary obstruction, or distal biliary stent dysfunction are eligible. Randomization will take place once adequate biliary drainage is achieved by ERCP. Main exclusion criteria are concomitant pancreatitis, liver abscess, cholecystitis, and another infectious diagnosis at the time of randomization, use of systemic maintenance antibiotics, and specific immunosuppressants. Patients will be stratified for blood culture results at the time of randomization and aetiology of cholangitis. The primary endpoint is clinical cure, defined as the patient being symptom-free by day 14, with no relapse or death occurring by day 30. Secondary endpoints include 30-day and 90-day all-cause mortality, relapse of cholangitis by day 90, time from ERCP to first relapse, any other subsequent infection requiring antibiotic treatment within 90 days, duration of initial hospital stay, number of days treated with antibiotics by day 30, subsequent infections with multidrug resistant (MDR) bacteria, quality of life, and cost-effectiveness. DISCUSSION: This trial assesses whether a short course of antibiotic treatment for acute cholangitis is as safe and effective compared to a longer course of antibiotic treatment. If confirmed, the results could substantially reduce antibiotic exposure and healthcare resource utilization, thereby contributing to global efforts to minimize unnecessary antibiotic treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT05750966, registered on March 2nd, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Overdevest AG, Sieswerda E, Haal S, et al. Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. Trials. 2026. PMID: 41689066. doi:10.1186/s13063-026-09524-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。